REGISTER RECORD · clinicaltrials.gov
NCT00220194
A Six-Month, Open-Label, Crossover Study Of the Maintenance Of Serum Testosterone And PSA Suppression After Switching Between Lupron 22.5 Mg And Eligard 22.5 Mg Or Zoladex 10.8 Mg And Eligard 22.5 Mg In Patients With Advanced Prostate Cancer
AS THE REGISTER RECORDS IT
Status and dates
| Status as listed | COMPLETED: completed |
|---|---|
| Register last updated | 2016-10-14 |
| Retrieved by this site | 2026-10-03 |
| Source | https://clinicaltrials.gov/study/NCT00220194 |
What this record shows
This entry describes research activity. It is not a statement about market authorisation, and it is not regulatory, legal or medical advice: a trial being listed, completed or halted says nothing about whether a substance may be sold or used anywhere. Status wording is reproduced as the register writes it and is never mapped onto a simpler vocabulary.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.